PO.1.12 Transcriptome profiling and autoimmunity-related serological markers identify TP53 and C3aR as drug targets in neuropsychiatric systemic lupus erythematosus

• J Lindblom,
• MO Borghi,
• M Alarcón-Riquelme,
• C Mohan,
• J Castillo,
• G Barturen,
• I Parodis,
• E Iacobaeus,
• Y Enman,
• E Carnero-Montoro,
• D Toro-Domínguez,
• D Repsilber

Affiliations

J Lindblom

1Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital ~ Stockholm ~ Sweden

MO Borghi

1University of Milan, Milan, Italy

M Alarcón-Riquelme

Department of Genetics and Pathology, Rudbeck Laboratory, University of Uppsala, Uppsala, Sweden

C Mohan

Center for Immunology, Department of Internal Medicine/Rheumatology, University of Texas Southwestern Medical Centre, Dallas, Texas, USA

J Castillo

Service of Microbiology, University Hospital, Zaragoza, Spain

G Barturen

1Centro de Genómica e Investigación Oncológica (GENYO), Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain

I Parodis

1Karolinska Institutet, Stockholm, Sweden

E Iacobaeus

Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institute, Stockholm, Sweden

Y Enman

1Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital ~ Stockholm ~ Sweden

E Carnero-Montoro

1GENYO. Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional Government ~ Granada ~ Spain

D Toro-Domínguez

2GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain, Medical Genomics ~ Granada ~ Spain

D Repsilber

6School of Medical Sciences, Örebro University ~ Örebro ~ Sweden